PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCLAdam Sharp, Hendrick-Tobias Arkenau, Sarah P. Blagden et al.|HemaSphere|2022Cited by 5
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patientsSarah P. Blagden, David J. Harrison, S.N. Symeonides et al.|Annals of Oncology|2024Cited by 3